Current Treatment and Recent Progress in Gastric Cancer
Perioperative FLOT resulted in superior overall survival compared to ECF/ECX (median OS 50 months vs. 35 months).
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Precision medicine in gastric cancer
- Gastric cancer
- DESTINY‑Gastric05 Phase 3 Trial of ENHERTU Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer
- Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies
- Nivolumab/Chemo Yields Long-Term Survival in Advanced Gastric Cancers